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Preterm birth places infants in an adverse environment that leads to abnormal brain
development and cerebral injury through a poorly understood mechanism known to
involve neuroinﬂammation. In this study, we integrate human and mouse molecular and
neuroimaging data to investigate the role of microglia in preterm white matter damage. Using
a mouse model where encephalopathy of prematurity is induced by systemic interleukin-1β
administration, we undertake gene network analysis of the microglial transcriptomic response
to injury, extend this by analysis of protein-protein interactions, transcription factors and
human brain gene expression, and translate ﬁndings to living infants using imaging genomics.
We show that DLG4 (PSD95) protein is synthesised by microglia in immature mouse and
human, developmentally regulated, and modulated by inﬂammation; DLG4 is a hub protein in
the microglial inﬂammatory response; and genetic variation in DLG4 is associated with
structural differences in the preterm infant brain. DLG4 is thus apparently involved in brain
development and impacts inter-individual susceptibility to injury after preterm birth.
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The majority of preterm infants develop encephalopathy ofprematurity characterised by oligodendrocyte maturationarrest, hypomyelination and reduced brain growth1–3.
This is associated in over 30% of infants with long-term
neurocognitive problems4, 5, and has characteristic correlates
on magnetic resonance imaging (MRI) and diffusion MRI
(d-MRI)6, 7. It is strongly associated with systemic and
cerebral inﬂammation, with the prominent involvement of
microglia2, 8–10.
Microglia are found preferentially within the developing white
matter2, 11 and have both pro-inﬂammatory and restorative
functions that are essential for normal brain development12, 13.
However, the microglial response to preterm birth is poorly
understood and a better understanding of microglial function in
this context could allow therapeutic modulation to mitigate
the brain injury of prematurity and other cerebral inﬂammatory
conditions.
We have used integrative genomics to investigate the role of
microglia in preterm brain development, employing a clinically
relevant mouse model of interleukin-1β (IL1B)-induced systemic
inﬂammation that recapitulates the essential features of the
encephalopathy of prematurity14, integrating microglial-speciﬁc
data from this model with ex vivo and in vitro experiments,
analysis of human microglia and imaging-genomic data
from preterm infants.
We now report: (a) endogenous expression of DLG4 (PSD95)
by microglia in early development, which is modulated by
developmental stage and inﬂammation; (b) a role for DLG4 as
a hub protein in the microglial inﬂammatory response; and (c) an
association between genetic variability in DLG4 and white matter
structure in the preterm neonatal brain.
Results
Global effects of IL1B on mouse microglial transcriptome.
In a previously validated mouse model of encephalopathy of
prematurity in which IL1B is administered intra-peritoneally
from postnatal days 1–514 (Fig. 1a), we veriﬁed that microglia
were the predominant myeloid cell in the brain (Supplementary
Fig. 1a, b) and that the blood-brain barrier remained appreciably
intact, with increased expression of tight junction and adherens
genes (Supplementary Fig. 2a-d). P5 is comparable with
human gestational age around 32 weeks15. CD11B+ cells were
then isolated by magnetic-activated cell sorting (MACS) at
postnatal days 1, 5, 10 and 45, and ﬂuorescence-activated cell
sorting (FACS) and qPCR analysis used to demonstrate these cells
to be >95% pure microglia (Supplementary Fig. 1c–e). These
isolated ex vivo microglia were then used for microarray gene
expression analysis.
We examined the effects of systemic IL1B on the microglial
transcriptome by: (a) comparing systemic IL1B exposure with
control conditions (“IL1B”); (b) examining transcriptional
changes over time (“Development”) and; (c) assessing
whether there is a different transcriptional response to IL1B as
a function of time (“Interaction”). Development captured
development of microglia themselves as well as systemic
maturation, and the interaction assessed whether IL1B effects
were time dependent.
After accounting for multiple testing, we found thousands of
genes with altered expression in each of the three responses
(Supplementary Data 1). Functional enrichment analysis of
the differentially expressed genes implicated numerous
biological processes and pathways (Supplementary Fig. 3 and
Supplementary Data 2 and 3). IL1B and Development
showed some interdependency, with over-representation of
cytokine-cytokine receptor interaction, transmembrane signalling
and cell adhesion molecules. Using REVIGO16, we deﬁned a set
of representative gene ontology (GO) processes common to IL1B
and Development, including immune system processes, cell
adhesion, morphogenesis, regulation of multicellular organismal
process and cell surface receptor signalling (Supplementary
Data 4). IL1B exposure during development thus has a pervasive
effect on the microglial transcriptome, engaging pathways
relevant to both immune function and growth.
Patterns of microglia gene expression response to IL1B. When
expression proﬁles were clustered by their response to IL1B at
each time point, several gene clusters became apparent (Fig. 1b
and Supplementary Fig. 4), with the most prominent clusters
observed at P1 and P5 (Z-score above 1 or below −1, difference
between IL1B and control p< 0.05, false discovery rate (FDR)=
10%, two-sample Welch t-statistics, adjusted with Benjamini
and Hochberg FDR controlling procedure). Functional annota-
tion (Fig. 1c and Supplementary Data 5) revealed inﬂammatory
genes upregulated at P1 and P5 in two distinct waves: an
immediate response at P1 and a subsequent early response at P5.
In contrast, processes related to anatomical development and
DNA replication were downregulated at P1, and cell structure
and binding-related processes were downregulated at P5. This
transcriptional pattern was neutralised by P10 with suggestion
of a reversal by P45, which was not quantiﬁed further. Systemic
IL1B thus induces a rapid transcriptional response in microglia
that prioritises inﬂammatory functions over growth.
Gene co-expression network analysis. Gene and protein
network-based analysis uncovers processes involved in disease17,
with topological measures being informative of underlying
biology18. The functionally coherent gene clusters suggested gene
co-regulation, and an analysis using graphical Gaussian models19
revealed characteristic co-expression networks emerging in
response to IL1B (IL1B), over time (Development), or with a
differential response to IL1B over time (Interaction) (Fig. 2).
The three networks showed distinct gene membership and
function, with only 22 genes in common (Supplementary Table 1),
and notable topological differences (Supplementary Table 2).
The Development network had small world topology with a
high clustering coefﬁcient and degree exponent close to 2. In
contrast, the IL1B network was bigger and more homogenous,
and although there were genes with high degree (i.e., hub genes
with many other genes connected to them) this did not result
in the formation of obvious subclusters. The Interaction network
has a topological structure intermediate to the other two networks
(Fig. 2, lower panel, and Supplementary Movie 1). This suggests
that IL1B disrupts the normal small world topology, leading to a
transcriptional response akin to the genomic storm previously
noted in human leukocytes following severe inﬂammatory
stress20.
Functional enrichment analysis showed that differences in
network topology were paralleled by different biological processes
and pathways (Supplementary Fig. 5 and Supplementary Data 6),
with no overlap between the annotation categories (GO terms or
Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways)
for IL1B and Development networks. The IL1B network was
predominantly enriched for GO terms related to defence
response, transmembrane signalling and channel activity. The
Development and Interaction networks encompassed broad
functional categories, spreading the networks’ genes among
many different categories, so that enrichment results rarely
survive multiple testing correction; nominally signiﬁcant
functional enrichment terms are therefore included for the
annotation of the Development and Interaction networks (Fig. 2,
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top panel). This annotation implies that differences between gene
networks are reﬂected at the functional level, with IL1B activating
immune responses, while Development and Interaction have
broader biological functions.
Protein-protein interactions and neuropsychiatric genes.
We asked whether these co-expression relationships are
conserved at the protein level and relevant to neuropsychiatric
disorders linked to brain development and prematurity. The
genes from all three co-expression networks were combined and
their shared interactome investigated by searching for
known protein-protein interactions (PPI) to highlight
functional interactions, an approach previously shown to be
useful for disease gene prioritisation21. We used a curated data set
to build a robust PPI network22 and then carried out a
power graph analysis (PGA)23 to identify simpliﬁed coherent PPI
networks. Power graphs are lossless representations of graphs
based on power nodes (sets of nodes brought together) and power
edges (connecting two power nodes, so that all the nodes in the
ﬁrst power node are connected to all the nodes in the second
power node). To further rationalise the power graph structures,
we introduce the term super-power node (SPN) to refer to a set of
power nodes that form a connected graph. When applied to all
genes present in the three co-expression networks, we identiﬁed
high-conﬁdence connections between 96 proteins. The PGA
revealed that 71 of these proteins belong to either one of two
main SPNs: SPN1 or SPN2 (Fig. 3 and Supplementary Fig. 6).
To corroborate the identiﬁcation of these two SPNs
independently, we used a separate approach (DAPPLE)24, which
interrogates a large database of experimentally derived PPI to
assess the physical connections among proteins encoded by the
genes of interest. In this case, the signiﬁcance of the PPI derived
from the input gene list is assessed empirically. This analysis
replicated the identiﬁcation of 23/46 edges from SPN1 and 36/41
edges from SPN2, providing empirical support for the
signiﬁcance of these PPI (permutation-based p value <0.001,
Supplementary Fig. 7).
PPIs have rarely been measured in the context of distinct cell
types, tissues or in speciﬁc disease conditions, making it
challenging to model and understand context-related phenotypes,
but it has been shown that heterogeneous genomic data
contain functional information of protein-DNA, protein-RNA,
protein-protein and metabolite-protein interactions25, 26.
We therefore sought additional external validation of cell-type
speciﬁcity for SPN1 and SPN2 by querying the GIANT database
of tissue-speciﬁc gene networks that includes mapping to tissue
and cell-lineage-speciﬁc functional contexts17. Glia-speciﬁc gene
interactions within SPN1 and SPN2 were reconstructed with high
conﬁdence from this prior experimental data (Supplementary
Fig. 8a), further supporting the consistency and speciﬁcity of our
ﬁndings.
Genes coding proteins in the SPNs came from all three
gene networks with minimal overlap (Supplementary Fig. 9),
suggesting different transcriptional networks (Fig. 2) might
converge to less redundant structures at the protein level (Fig. 3),
probably reﬂecting the known modular architecture of PPI
networks27 reﬂected in the identiﬁcation of SPN1 and SPN2.
Functional annotation of the two SPNs indicated that these
are distinct in function, with SPN1 being signiﬁcantly
enriched for proteins involved in nervous system
processes and SPN2 for cell signalling and transcriptional
regulation (Fig. 3 and Supplementary Table 3). Consistent
with this, SPN1 showed tissue expression speciﬁc to the brain,
whereas SPN2 had a broader tissue distribution (Supplementary
Data 7 and 8).
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We tested whether SPN members were enriched for genes
involved in brain disorders. The gene disease annotation tool28
showed that SPN1 is signiﬁcantly and speciﬁcally enriched for
autism and schizophrenia (p< 0.05, 10,000 permutations28)
(Supplementary Data 9). SPN2 has a broader though similar
enrichment within the psychology and psychiatry category
(Supplementary Data 9), alongside a very general enrichment
across all systems (Supplementary Data 10), implying an
important but less speciﬁc role in brain disorders. The
WebGestalt tool independently showed speciﬁc enrichment in
SPN1 for genes involved in brain disease29 (hypergeometric test,
adjusted p< 0.05, Supplementary Table 4).
These analyses suggest that the gene co-expression relation-
ships observed in microglial cells after in vivo IL1B treatment are
at least in part conserved at the protein level, and can be
synthetised by two major PPI modules, which represent
functional modules in PPI networks. These are functionally
distinct, with SPN1 speciﬁcally enriched for genes involved in
neuropsychiatric disorders linked to prematurity, such as DLG4
in schizophrenia and autism30–32, SHANK1 in autism33 and
CAMK2A in several phenotypes34.
Transcriptional regulation of SPNs. We examined the potential
regulation of SPN1 and SPN2 by transcription factors (TFs) and
searched for potential regulatory relationships mediated by TFs,
which can determine coordinated expression of several target
genes.
Analysis of transcription factor-binding site (TFBS) motifs
using the PASTAA algorithm35 indicated that an SPN2 member,
STAT3 (signal transducer and activator of transcription 3), as
well as other members of the signal transducers and activators of
transcription (STAT) family of TFs (STAT6 and STAT1-alpha),
are signiﬁcantly predicted to bind the promoters of 22/36 (61%)
members of SPN1 (hypergeometric test, p< 0.05, Supplementary
Tables 5–7). The link between the STAT family of TFs and genes
in SPN1 was also supported by an independent analysis using the
gene set enrichment analysis tool in the molecular signatures
database (Broad Institute)36 to assess the overlap between 615
gene sets (containing genes that share a common TFBS) and the
genes in SPN1/2. This showed a signiﬁcant association of
members of SPN1 (Med13, Kcnj16 and Iﬁt3) with STAT1 and
STAT2 TFs (FDR= 2.8%), further supporting a link between
SPN2 and SPN1 via the STAT family of TFs.
To seek additional experimental support for the predicted
interaction between SPN1 members and the STATs TFs, we
investigated the genomic distribution of binding sites of the
family of signal transducers and activators of transcription
(STAT1, STAT3 and STAT5) in a data set of lipopolysaccharide
(LPS)-stimulated primary microglial cultures37. Chromatin
immunoprecipitation-promoter microarray data (ChIP-Chip)
indicated STAT binding at the promoters of 8/35 (22%) of the
genes in SPN1 with any of STAT1, STAT3 or STAT5
(Supplementary Table 8). On inspection of the STAT3 TF gene
expression response to IL1B exposure (Supplementary Fig. 10a),
its mRNA level was found to be signiﬁcantly higher at P1 in
microglia exposed to IL1B vs. controls, and signiﬁcantly lower at
P5 (FDR= 0.1%). At P1, the mRNA levels of the 22 predicted
transcriptional targets of STATs in SPN1 vary, with log2 ratios in
the range −1.02 to 1.24 (Supplementary Fig. 10b). These results
support a potential link between SPN2 and SPN1 (Supplementary
Fig. 10c), and suggest that STAT3 TF in SPN2 may regulate SPN1,
perhaps through early Stat3 gene activation in IL1B-exposed cells,
as previously reported38.
Conﬁrmation of effects of STAT3 TF on SPN members. Using
CD11B+ cells MACS-isolated at P1 and exposed to a vehicle
solution or IL1B + IFNg (chosen because they are highly regulated
in the brains of IL1B exposed mice (Gressens, unpublished data)
and cause a moderate but consistent inﬂammatory reaction
in vitro39, 40), we tested the transcriptional role of STAT3 in the
interaction between SPN1 and SPN2 by STAT3 pharmacological
inhibition followed by RT-qPCR. MACS-isolated microglia were
stimulated by IL1B + IFNg and exposed to vehicle or a small
molecule inhibitor of STAT3 (BP-1-102) that binds to the
three subpockets of STAT3 SH2 domain and blocks STAT3
phosphorylation, dimerization and DNA-binding activity. Gene
expression for a set of genes representing general microglia
function markers and a subset of genes from SPN1 and SPN2 was
measured by qPCR (Supplementary Table 13). The proﬁles and
features of the markers were previously characterised by us with
in vitro microglia39. Given the high purity of the MACS-isolated
CD11B+ cells (>95% microglia, Supplementary Fig. 1), we
employ them as markers of general microglia activity states and a
means of assessing the potential role of the cell rather than for the
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purposes of cell-type speciﬁcity. We used 11 markers broadly
grouped as markers of classic pro-inﬂammatory actions (Ptgs2,
Cd32, Cd86 and Nos2), immunomodulatory markers (Il1rn, Il4ra,
Socs3 and Sphk1) and regenerative function markers (Lgals3, Igf1
and Cd206)39. IL1B + IFNg induced expression of several
pro-inﬂammatory and immunomodulatory markers and
repressed expression of regenerative markers as expected. STAT3
inhibition decreased expression of three of the four
pro-inﬂammatory markers (Cd32, Cd86 and Nos2), but had no
signiﬁcant effect on the repression of regenerative markers. By
contrast, IL1B + IFNg reduced expression of immunoregulatory
marker Socs3, while Sphk1 expression was increased by STAT3
inhibition (Supplementary Fig. 11).
Regarding the analysis of genes from SPN1 (Dlg4 and Notch1),
we found no effect on Dlg4 of inﬂammation or STAT3 inhibition.
This lack of response of Dlg4 gene expression to IL1B is
supported by the microarray measurements at P1, which show
no signiﬁcant difference between IL1B and control (PBS)
(Supplementary Fig. 10, Student’s t test, p= 0.32). However,
expression of DLG4 protein in neurons is strongly regulated by
post-translational modiﬁcations, and these data may not provide
reliable information on changes at the protein level. Notch1 gene
expression was also unaffected by either inﬂammation or STAT3
inhibition. For the analysis of SPN2 genes, we observed that IL1B
+ IFNg exposure signiﬁcantly increased expression of Stat3, and
STAT3 inhibition signiﬁcantly decreased Arnt2 and Hif1a
(Supplementary Fig. 11).
Taken together, these data conﬁrm that IL1B + IFNg exposure
induces both pro-inﬂammatory and immunomodulatory
microglial responses, and that STAT3 presence is required
for the pro-inﬂammatory response and typical modulatory
component to occur. The transcriptional relationship between
SPN1 and SPN2 in the context of inﬂammation is less clear, and
possibly post-transcriptional.
DLG4 is central to SPN1 and has a novel role in microglia. To
clarify how the systemic IL1B inﬂammatory stimulus leads to
speciﬁc neuronal and neurological effects, we focused on DLG4, a
member of the membrane-associated guanylate kinase family.
DLG4 has not previously been known to have a function in
microglia, but is the hub protein of SPN1 (Fig. 3), and has
an established neurodevelopmental role in synaptic plasticity in
neurons41. Our data suggest the hypothesis that DLG4 plays a
role in the brain’s response to inﬂammation and may be a
potential link between inﬂammation and both preterm brain
injury and neuropsychiatric disease.
DLG4 at the microglial membrane is dynamically modulated.
We investigated whether DLG4 protein could be observed in
mouse microglia, and whether this is modulated by IL1B
and development. We assessed immunoﬂuorescence both in
MACS-isolated CD11B+ cells cultured from P1 mice (Fig. 4 and
Supplementary Fig. 12), and in tissue sections from pups expo-
sed to IL1B from P1 to P3 (Supplementary Fig. 13). Under
control conditions at P1, microglia produce DLG4 protein that is
localised to the cell membrane (>95% of IBA1+ cells stained for
DLG4) (Supplementary Movie 2). This DLG4 staining disappears
by P3 (Supplementary Fig. 13, postnatal day 1 and 3 PBS overlay),
and the protein is still absent from IBA1-positive cells at P45.
Following exposure to IL1B, DLG4 was detected at the microglial
membrane at both P1 and P3 (Supplementary Fig. 13, postnatal
day 1 and 3 IL1B overlay) but not P45, suggesting a delay rather
than a permanent change in development, consistent with current
hypotheses42.
Microglia synthesise endogenous DLG4 in early development.
To verify that DLG4 protein detected in microglia is
endogenously synthesised, rather than the phagocytosed synaptic
debris seen later in development43, we stained for DLG4 and
lysosomal-associated membrane protein 1 (LAMP1), a marker
of lysozymes. No co-localisation of these markers was
demonstrable in IBA1+ cells, with LAMP1 immunoﬂuorescence
mainly conﬁned to intracellular vesicles and DLG4
consistently and clearly at the microglial cell membrane
(Supplementary Fig. 14). A 3D reconstruction of DLG4 and IBA1
immunoﬂuorescence showed evident membranous staining
(Supplementary Movie 2). In addition, in the developing cortex
at P1 and P3, DLG4 protein staining was absent from cells not
expressing IBA1. At P5, we observed DLG4 protein in a limited
number of putative cortical neurons, in keeping with the reported
normal developmental expression in the cortex in mice and
comparative time points in humans44. We also found DLG4
protein at the membrane of MACS-isolated primary mouse
microglia maintained ex vivo for 96 h, in the absence of neurons
(Supplementary Fig. 12).
DLG4 is expressed in developing and adult human brain tissue.
Interrogating the BrainCloud resource45, we found the DLG4
gene expressed in human cortex from early fetal development
(14+ gestational weeks (GW)) throughout life, with
expression increasing rapidly during the ﬁrst year (Supplemen-
tary Fig. 15a)46. The BrainSpan Atlas of the developing human
brain47 additionally suggests a relatively robust expression from
early gestation with an apparent decrease in DLG4 expression at
around 21 GW, then increasing values from 37 GW (Supple-
mentary Fig. 15b). The Allen Brain Atlas Brain Explorer48
indicates widespread cortical expression in adulthood (Supple-
mentary Fig. 15c) and the UK Brain Expression Consortium
(UKBEC) database49 records DLG4 widely expressed in both
grey and white matter in adults (Supplementary Fig. 8c).
However, DLG4 mRNA is targeted for degradation via speciﬁc
post-translational modiﬁcations and may not be strictly pre-
dictive of protein levels50.
DLG4 is expressed by microglia in the developing human
brain. We then assessed cell-type speciﬁc expression of DLG4
protein from microglia of the developing human brain in isolated
CD11B+ cells and in tissue sections. In MACS-isolated human
fetal microglia at 19 and 21 GW (roughly equivalent to P1 in
mouse15) DLG4 protein co-localised with IBA1 (Supplementary
Fig. 16); this staining appeared to increase with activation of
microglia to a pro-inﬂammatory state using LPS. Further, we
stained human fetal brain sections through the dorsal cortex.
At 20 GW, there was co-localisation of IBA1 and DLG4 protein
(Fig. 5) limited to cells in the proliferative zone, and the absence
of any other DLG4-positive cells. At 26 GW, IBA1 and DLG4
again co-localised, but DLG4 was also detected in sparse cells,
putative neurons, in the cortex. At 30 GW, we noted very few
IBA1 and DLG4 co-localised cells, but many DLG4-positive cells
in the cortex.
DLG4 is thus widely expressed in the human brain during
development with synthesis of DLG4 protein by human microglia
at a time when there appears to be minimal expression by
neurons.
DLG4 gene variants and matter structure in preterm infants.
To assess whether the DLG4 gene might be important in infants
surviving preterm birth, we undertook an imaging-genomic
analysis. We focused on white matter, which has a well-
established correlation with outcome6, 7, 51, and a high
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microglia content particularly at this stage of development2, 52.
d-MRI brain images for two separate cohorts of preterm
infants (n= 70 and 271, Supplementary Table 9) were acquired at
term-equivalent age, and a measure of white matter
microstructure known to be affected by prematurity (fractional
anisotropy, FA) was extracted using tract-based spatial statistics
(TBSS) (Supplementary Methods). DNA extracted from saliva
was genotyped on the Illumina HumanOmniExpress-12 array.
Seven single nucleotide polymorphisms (SNPs) on this array
mapped to DLG4 (Supplementary Table 10), including
rs17203281, which has previously been associated with
neuropsychiatric disease, signiﬁcantly predicting schizophrenia
risk53, 54 and changes in cortical regional volume in patients with
Williams’ syndrome, a well-characterised genetic syndrome
overlapping with autism31.
Infants in both cohorts were categorised by presence or
absence of the minor allele (A) for DLG4 at rs17203281 to test for
the effect of minor allele load (minor allele frequency (MAF) in
cohort 1 (pilot)= 0.22; MAF in cohort 2 (replication)= 0.28), and
a general linear model was used to test for a correlation between
genotype and white matter FA. This analysis showed a signiﬁcant
difference (p< 0.05, family-wise error (FWE)-corrected by
threshold-free cluster enhancement, FDR=10%) in FA between
infants with or without the minor allele (A) for SNP rs17203281
in both cohorts (Fig. 6). There were no signiﬁcant differences in
other clinical features (gestational age at birth, age at scan, days of
ventilation, incidence of chorioamnionitis, bacterial sepsis or
necrotising enterocolitis, Supplementary Table 15) between
infants with or without the minor allele. None of the other SNPs
at the DLG4 locus had a replicable effect in both cohorts.
To investigate whether the observed effect of common genetic
variation in DLG4 is speciﬁc to this gene or could be extended to
SPN1 genetic variants as a group, we used a list of all genes in
SPN1 as a set of interest and carried out association testing with
the phenotype using joint association of genetic variants55 in the
larger cohort of 271 infants. This tests the null hypothesis of there
being no more evidence for association of common genetic
variants (SNPs) in genes from SPN1 with the phenotype under
study than any other random set of an equal effective number of
SNPs (see “Methods” section). The SPN1-gene set was tested for
association with the real phenotype (query data), and this was
repeated with 1000 permutations of the phenotype (self-
contained test) to estimate empirical p values. This analysis
showed no signiﬁcant effect of the genes in SPN1 on FA,
supporting the speciﬁc association of DLG4 with white matter
features in the developing brain rather than a wider and more
general effect of the larger SPN1 network.
eQTL effect of DLG4 in human brain. We then queried whether
rs17203281 in the DLG4 region might be regulating DLG4 mRNA
expression, and searched for a possible expression quantitative
trait locus (eQTL) effect. We analysed DLG4 mRNA expression
within individual tissues in the brain, treating the expression
levels of the gene as a quantitative trait, so that variations in
gene expression that are highly correlated with genetic variation
can be identiﬁed as eQTLs. A SNP located within or in close
proximity to a gene that is signiﬁcantly associated with the gene’s
mRNA variation deﬁnes a cis-acting eQTL. We returned to the
UKBEC database and extracted genotypes for the rs17203281
plus DLG4 gene expression in the white matter, and compared
gene expression levels to genotypes. This analysis suggested that
normal individuals homozygote for the rs17203281 minor allele
(AA) genotype have a signiﬁcantly higher expression of DLG4 in
white matter than those with the alternate genotypes (AG or GG)
(Student’s t test, p< 0.05), suggesting a cis-eQTL effect for
rs17203281 (Supplementary Fig. 17).
To cross-validate this result, we queried the GTEx portal,
which provides a searchable resource of multiple different human
tissues with genotyping, gene expression proﬁling, whole-genome
sequencing and RNA sequencing data56. This revealed that DLG4
is preferentially expressed in the brain (Supplementary Fig. 8b),
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Fig. 5 Co-localisation of DLG4 protein and microglial marker IBA1 in the
developing human brain. Representative photomicrographs from the
subplate (SP) and subventricular zone (SVZ) through the dorsal cortex of a
20 GW (upper two rows) and 26 GW (lower row) human brain. No IBA1
PSD95 co-localisation was observed at 30GW. In green IBA1+ microglia
(IBA1), in red DLG4 (PSD95) protein and ﬁnal column shows co-localisation
of IBA1 and DLG4, together with DAPI nuclear staining. Arrows in top rows
point to area of distinct co-localisation at ×20 and a higher magniﬁcation is
shown of a single double-stained cell in the lower panel. Scale bar two top
rows= 40 µm and lower row= 10 µm
Voxels in white matter with significant difference in FA
between individuals with and without DLG4 minor allele
in replication cohort  
Cohort Individuals Effect of DLG4 p-value FDR Effect of SPN1
Pilot 70 Yes 0.05 25% NA
Replication 271 Yes 0.05 10% No
Fig. 6 3T d-MRI brain images for two cohorts of preterm infants acquired at
term-equivalent age (Pilot: cohort 1, n= 70; Replication: cohort 2, n= 271).
Images from replication analysis (cohort 2) shown. Views= sagittal,
coronal, axial (left-right). Coloured voxels have signiﬁcantly different
diffusion features (fractional anisotropy, FA) between infants with or
without the minor allele for DLG4 (n= 271, threshold-free cluster
enhancement (TFCE) p value <0.05, FDR=10%81). Table inset: replication of
ﬁndings in two independent cohorts of preterm infants
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and has multiple SNPs regulating its expression levels in cis
(Supplementary Table 11), of which one SNP (rs3826408) is in
high linkage disequilibrium (i.e., is a proxy SNP) with rs17203281
(r2= 0.667, D′= 1). Together, these analyses suggest cis-acting
genetic regulation of DLG4 mRNA expression in the brain by
rs17203281.
Overlaps between SPNs and neuropsychiatric gene modules.
Rare genetic variants in DLG4 have previously been associated
with autism, schizophrenia and epilepsy30. This identiﬁed DLG4
within a small module of 24 genes involved with synaptic
function, in which de novo and more severe missense mutations
were more likely in individuals with signiﬁcantly higher
intellectual impairment. We investigated the overlaps between the
main gene modules reported in ref. 30 and genes in SPN1 and
SPN2 using a formal test for intersecting gene lists57 (Supple-
mentary Fig. 18 and Supplementary Table 12). We found that
there were signiﬁcant overlaps between SPN1/2 and the reported
disease-associated modules. In particular, DLG4 was the most
frequently occurring gene in these overlaps (11/51 occurrences)
followed by another gene from SPN1, CAMK2A (4/51). Notably,
SPN1/2 were broadly captured by the autism modules 1/2
reported in ref. 30.
Discussion
The primary ﬁnding of this study is that DLG4 is expressed
in microglia during early development in a developmentally
regulated expression pattern that is altered by neuroinﬂammation
associated with brain damage in preterm born infants. This is a
novel role for DLG4, previously considered an archetypal
marker of the neuronal post-synaptic density.
The IL1B administration model used here captures essential
features of the encephalopathy of prematurity including
hypomyelination linked to oligodendrocyte maturation arrest,
microglial activation, cognitive deﬁcits, decreased fractional
anisotropy on MRI and axonopathy14. Systemic IL1B generated
two waves of gene expression in microglia, with upregulation
of inﬂammatory genes and downregulation of genes involved in
growth, creating a genomic storm20 that altered the normal gene
and protein network topology. DLG4 was the hub of the SPN1
protein network that is highly enriched with genes implicated
in neurocognitive disorders. SPN1 has a star conﬁguration,
which appears to maximise network efﬁciency at the expense
of robustness, since perturbing the central hub broadly disrupts
the system58. Hub proteins are important for cellular growth,
under tight regulation, continuously evolving59, and more
intrinsically disordered than proteins with fewer relations60.
DLG4 is the only member of either SPN1 or SPN2 that qualiﬁes
as a hub, and is signiﬁcantly enriched for disorder promoting
amino acids (Student’s t test, p< 0.02)61.
SPN1 interacted with SPN2 via the transcriptional regulation
by STAT3, a TF previously linked to microglial activation and
neuroprotection pathways62. The combined PPI and TF analysis
revealed a possible functional relationship between two protein
interaction sub-networks. The same relationship was not
observed between the STATs TFs and genes in SPN2.
Microglia DLG4 protein synthesis at P1 disappears by P3,
unless this developmental pattern is disrupted by inﬂammation
leading to the temporary persistence of DLG4 at the cell
membrane, which resolves by P45. The disappearance of
DLG4 protein between P1 and P3 could be due to
post-transcriptional mechanisms involving micro-RNAs,
mRNA degradation and post-translational mechanisms affecting
protein localisation as previously observed in neurons (review
in ref. 50). Inﬂammation-induced persistence of DLG4 protein
may be a previously unappreciated mechanism of inﬂammatory
brain injury.
In human infants, we found developmentally regulated
DLG4 gene expression throughout brain tissue. In mouse and
human microglia, DLG4 protein localised to cell membranes
and was not found within cytosolic vesicles: DLG4 detection was
thus not due to the participation of microglia in synaptic pruning
seen later in development43, reﬂecting the well-known role of
DLG4 in synapse structure and development32, 41, 46; indeed this
is consistent with previous data showing that DLG4 mRNA was
not expressed in neurons before P5-1044.
Common genetic variation in DLG4 (rs17203281) was
associated with structural white matter changes in two
independent infant cohorts, possibly due to measured differences
in expression of DLG4 mediated through a posited cis-eQTL
action of rs17203281, suggesting that inter-individual genetic
variability in DLG4 gene could affect the response to perinatal
inﬂammation. Preterm infants have an increased risk of
developing autism spectrum disorders (ASD) and other
neuropsychiatric disorders, and DLG4 has been consistently
associated with neuropsychiatric diseases including ASD and
schizophrenia30, 63 (Supplementary Data 11), while mice with
Dlg4 deletion (Dlg4−/−) exhibit increased repetitive behaviour,
abnormal communication and social behaviour31.
The observed changes in d-MRI are characteristic of
encephalopathy of prematurity. However, d-MRI provides no
information on the cell types involved in these microstructural
abnormalities, and the relationship between DLG4 variability
and brain structure cannot be attributed speciﬁcally to microglia.
Nevertheless, white matter is highly populated with microglia in
the perinatal period in both humans and mouse52, and even
in adults microglia are typically much more numerous in white
matter than in neocortex64. TBSS provides a powerful approach
to d-MRI data, providing group analyses that overcome problems
of partial volume effects. However, TBSS is highly dependent
on the quality of the image registrations65, 66, and as this is
particularly challenging in developing brain, we have created an
optimised neonatal pipeline and characterised the sensitivity of
TBSS in this population67, 68. In addition, although TBSS is a
powerful technique for identifying associations with white matter
microstructure, it is less reliable for precise spatial localisation
within white matter.
The mechanism of DLG4 action in microglia remains unclear.
In vitro, inhibition of the interaction between DLG4 protein and
the N-methyl-D-aspartate receptor N2B subunit69 (which has a
moderate but signiﬁcant effect on microglial activation state
and response to perinatal injury70) had no effect on microglia
phenotype. We conjecture that the role of DLG4 in microglia may
be in the domain of cell-cell communications, such as cross-talk
between oligodendrocytes, astrocytes and microglia71 or
regulation of glutamatergic and GABAergic signalling72. Of
interest, DLG4 may be involved with the clustering and activity
of inwardly rectifying potassium channels (Kir) predominantly
expressed in glial cells73. Microglial Kir have functional effects on
microglial activity and could have therapeutic applications in
Alzheimer’s and Parkinson’s diseases74. DLG4 has also been
observed in oligodendrocytes and may mediate Kir-related
myelination75.
The inﬂammatory reﬂex involving the vagus nerve76 could
attenuate the IL1B response in vivo, and microglia activity may be
modulated via microglial α7 nicotinic acetylcholine receptors
(α7AChRs) that limit microglial activation77, possibly signalling
via NRG/ErbB4 interactions with DLG4 in microglia78 or via
endothelial COX279. This might be a fruitful area for further
discovery. It is also unclear how much the microglial response is
conditioned by cellular development and context, and whether
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this might differ between the in vivo and in vitro settings, as
well as between mouse and human. The topic of microglial
development including how to best characterise it in relation to
function requires further work.
Methods
Animal model. Experimental protocols were approved by the institutional
guidelines of the Institut National de la Sante ́ et de la Recherche Scientiﬁque
(Inserm, France), and met the guidelines for the United States Public Health
Service’s Policy on Humane Care and Use of Laboratory Animals (NIH, Bethesda,
MD, USA). The experimental set-up for inducing inﬂammation-induced white
matter injury in the mouse has previously been described in detail14. In brief, a 5 μl
volume of phosphate-buffered saline (PBS) containing 10 μg/kg injection of
recombinant mouse IL1B or of PBS alone (control) was injected intra-peritoneally
twice a day (morning and evening) on days postnatal P1-P4 and once in the
morning on day P5. Animals were sacriﬁced 4 h after the morning injection of IL1B
at P1, P5, P10 and P45. Brains from animals at P1, P3 and P10 were also used for
immunoﬂuorescence with antibodies to detect DLG4, ((6G6-1C9) (Product# MA1-
045), Thermo Scientiﬁc; 1:500), ((IBA1) (ab5076, Abcam; 1:400) and LAMP1
(L1418, Sigma; 1:200). Details in Supplementary Methods.
CD11B+ microglia MACS in mouse. Brains were collected from mice for cell
dissociation, and microglia were isolated by magnetic antibody-based cell
sorting (MACS) using CD11B antibody (Miltenyi Biotec, Bergisch Gladbach,
Germany, dilution 1:10) (details in Supplementary Methods) according to the
manufacturer’s protocol using all recommended reagents and equipment. The
purity of MACSed CD11B+ fractions was validated using FACS analysis of CD11B
ﬂuorescence, and the purity was further validated with RT-qPCR of the positive
and negative CD11B cell fractions. Details in Supplementary Methods.
Gene co-expression network reconstruction. Mouse microglial RNA was
extracted and hybridised to Agilent Whole Mouse Genome Oligo Microarrays
(8 × 60 K). Three separate gene co-expression networks were reconstructed from
these data, showing a signiﬁcant response to IL1B, Development and Interaction
effect (Fig. 2). Details in Supplementary Methods.
PPIs and transcriptional regulation. The nodes of all three gene networks (IL1B,
Development and Interaction) were aggregated into one list and used to investigate
protein interactions with a PGA23, and two super-power nodes (SPNs) were
identiﬁed by examining which sets of power nodes were directly interconnected
(Fig. 3 and Supplementary Fig. 6). GO annotation and enrichment analysis
was carried out, and the transcriptional control of the protein networks was
interrogated using motif analysis and ChIP-Chip data37. Details in Supplementary
Methods.
Mouse cell culture studies. MACS-isolated microglia were stimulated by
IL1B + IFNg and exposed to one of: vehicle; a small molecule inhibitor of STAT3
(BP-1-102; Merck Millipore) or TAT-N-dimer (an inhibitor of the DLG4 protein
NMDA receptor interaction; Merck Millipore). At the end of the treatment period,
cells were harvested and used for immunoﬂuorescent labelling; mRNA was
extracted for gene expression analysis, and supernatant was collected for nitrites/
nitrates or cytokines/chemokines measurement. Antibodies used were a mouse
monoclonal antibody to detect DLG4 ((6G6-1C9) (Product# MA1-045), Thermo
Scientiﬁc; 1:500), a goat polyclonal antibody to detect IBA1 Ionized calcium
binding adaptor molecule 1 ((IBA1) (ab5076, Abcam; 1:400)), and a rabbit
polyclonal antibody to detect Lysosomal-associated membrane protein 1
((LAMP-1) (L1418, Sigma; 1:200)). Details in Supplementary Methods.
Developing human brain post-mortem studies. All human post-mortem tissue
(cells and tissues) was acquired with ethical approval at The French Agency of
Biomedicine (Agence de Biomédicine; approval PFS12-0011). Written informed
consent was received prior to donation of foetal tissue. For the collection of human
microglia, post-mortem tissue without any neuropathological alterations was
acquired from two individuals at 19 and 21 GW. MACS-isolated microglia were
obtained and used for treatment with DMEM (control) or LPS, as well as
immunoﬂuorescence analysis and RT-qPCR. Human brain sections were obtained
from post-mortem cases from medical abortions at 20, 26 and 30 GW for
non-neurological diagnoses, and stained for IBA1 (ab5076, Abcam; 1:400) and
DLG4 ((6G6-1C9) (Product# MA1-045), Thermo Scientiﬁc; 1:500). Details
in Supplementary Methods.
Infant MRI studies. Research was carried out in compliance with the Code of
Ethics of the World Medical Association (Declaration of Helsinki), with
approval from the NHS National Research Ethics Service (NRES), to the standard
of the associated granting agencies. Two independent cohorts of preterm infants
(cohort 1: n= 70; cohort 2: n= 271) were imaged at term-equivalent age on a
Philips 3-Tesla system (Philips Medical Systems, the Netherlands), with acquisition
of structural (T2-weighted fast-spin echo MRI and 3D-MPRAGE) and diffusion
(single-shot echo-planar diffusion tensor imaging (EPI DTI)) sequences. Details
in Supplementary Methods.
Infant genotyping. Saliva samples for both infant cohorts above were genotyped
on the Illumina HumanOmniExpress-12 array, as previously described80 (Sup-
plementary Methods). The genotype matrix was recoded in terms of minor allele
counts, including only SNPs with MAF ≥5% and ≥ 99% genotyping rate. Details
in Supplementary Methods.
Data availability. All new data are available from the authors on request, subject to
ethical restrictions. Expression proﬁling of human dorsolateral prefrontal data is
accessible in the NCBI GEO database under accession code GSE30272.
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